May 18, 2022 / 12:30PM GMT
Operator
Hello, and welcome to the Calliditas Therapeutics Audiocast with Teleconference Q1 2022. (Operator Instructions) And afterwards, there will be a question-answer session. I will now hand the call over to Renee Aguiar-Lucander, CEO. Please begin your meeting.
Renee Aguiar-Lucander - Calliditas Therapeutics AB(publ)-CEO
Thank you very much, and welcome to this Q1 2022 report from Calliditas Therapeutics. If you turn to Page 2 of the presentation, I would like to draw your attention to the disclaimer page related to forward-looking statements and refer you to the company's reports and other filings, including those which contain risk factor and other relevant sections of our public filings.
On this call today, I am joined by Andrew Udell, President North America; and Fredrik Johansson, Chief Financial Officer.
So if you turn to Page 3. So as you are all aware, it's the last quarter, Calliditas Therapeutics Q4, I would say, achieved a historic milestone in our history. We had our first commercial
Q1 2022 Calliditas Therapeutics AB Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot